Business Wire

European Union’s ‘Digital Market Act’ Is Good, but for Online Users - It’s Not Good Enough

28.3.2022 14:00:00 EEST | Business Wire | Press release

Share

Several international digital specialists have praised the EU’s Digital Market Act, but say its primary aim is to foster competition among tech companies while trying to reign in some of the tech giants. They say its primary focus is not protecting the personal information of digital users.

“The Digital Market Act definitely places some constraints on how some of these tech giants can use consumers’ personal data, but in terms of giving them control over their own personal information, it comes up short,” said Dr Paul Twomey, one of the lead authors of a report entitled Empowering Digital Citizens.

The report, culminating two-years of work, was presented at the Global Solutions Summit in Berlin, Germany on 28 March 2022. The annual conference brings together senior government officials with top-level academic researchers, NGO leaders, and international CEOs. It transforms research-based insights into policy recommendations for the Group of Seven (G7) and Group of 20 (G20) inter-governmental forums.

“The buying and selling of personal data is part of a $515 billion (USD) market,” says Professor Dennis J. Snower, the report’s other lead author. “Digital users are simply not a part of this transactional system and in many cases don’t even know that it exists, nor do they know who has their personal information or how it is being used. We want humane market dynamics to apply to all participants in the online economy.”

Under the Empowering Digital Citizens proposal, online users would be given control over who has access to the personally identifiable information they create. They can also, with the help of a representative, set the terms under which their data can be used (according to the law), and in return they need to ensure that their data is accurate and verified by trusted third parties. “Only the illicit drug market and online data aggregators refer to people as users,“ says Twomey. “These proposals transform that model. They empower a world of digital citizens able to reinforce their democratic rights and counter the forces of disinformation.”

Twomey and Snower represent the Global Initiative for Digital Empowerment (GIDE), which is made up of over 70 specialists from around the world, including policy experts, researchers, Internet technical experts, business people, security specialists and others. GIDE is an initiative of THE NEW INSTITUTE. Based in Hamburg, THE NEW INSTITUTE is an institute of advanced studies and a platform to find answers to the most pressing ecological, economic and political challenges of our time.

The two digital researchers say a major problem is that many online users of “free services” are given artificially restricted choices of either revealing large amounts of personal data (by agreeing to the terms and conditions of digital services) or being excluded from the economic and social interactions that define modern life.

The Empowering Digital Citizens initiative will make online and digital consumers part of the economic model that is currently invisible to the average consumer.

Access the report here: Empowering Digital Citizens. Access an FAQ on the initiative here: Q&A on Human-Centered Digital Governance.

Membership of the Global Initiative for Digital Empowerment is on page four of the Empowering Digital Citizens report.

About Dr. Paul Twomey: Dr. Twomey is co-lead of the Global Initiative for Digital Empowerment and Fellow and Initiative Director for Digital Governance at THE NEW INSTITUTE. He is a Fellow and Core Theme Leader for “managing information and technology in the public interest” at the Global Solutions Initiative. Twomey is also a Distinguished Fellow at the Centre for International Governance Innovation and a Commissioner of the Global Commission for Internet Governance. He is the former CEO of ICANN, the global coordination body of the Internet’s addressing system.

About Prof. Dennis J. Snower: Prof. Snower is co-lead of the Global Initiative for Digital Empowerment and is the director for the Socio-Economic Transformation programme at THE NEW INSTITUTE.. He is founder and President of the Global Solutions Initiative; Professor of Macroeconomics and Sustainability at the Hertie School, Berlin; Senior Research Fellow at the Blavatnik School of Government, Oxford; and Non-resident Fellow of Brookings Institution. He is co-lead of this project. He is Research Fellow at the Centre for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Georg Diez
The New Institute
Hamburg
Tel: +49 40 3008 2714
press@thenew.institute

Brad White
White Paper Communications LLC
San Diego, CA USA
bradwhite@whitepaper.tv
Tel. +1.301.365.3571
Telegram: @Brad_White_SD
WhatsApp: +1.301.365.3571
Signal: +1.301.365.3571
Skype – bradrwhite

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye